Evidence map›Paper›PMID 36985290›Full record

ArticleMicroorganisms2023

Identification of Z-Tyr-Ala-CHN

Jordi Doijen, Koen Temmerman, Christel Van den Eynde, Annick Diels, Nick Van den Broeck, Michiel Van Gool, Inha Heo, Steffen Jaensch, Marleen Zwaagstra, Mayra Diosa Toro and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 3 countries.

Jordi DoijenJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
Koen TemmermanJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
Christel Van den EyndeJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
Annick DielsJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
Nick Van den BroeckCharles River Laboratories, Turnhoutseweg 30, 2340 Beerse, Belgium.ORCID 0000-0001-5900-4813
Michiel Van GoolJanssen Cilag S.A., C/Jarama 75A, 45007 Toledo, Spain.
Inha HeoJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
Steffen JaenschJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.ORCID 0000-0001-5637-3154
Marleen ZwaagstraFaculty of Veterinary Medicine, Yalelaan 1, Virology Division, Department of Biomolecular Health Sciences, Infectious Diseases and Immunology, Utrecht University, 3584 Utrecht, The Netherlands.
Mayra Diosa ToroFaculty of Veterinary Medicine, Yalelaan 1, Virology Division, Department of Biomolecular Health Sciences, Infectious Diseases and Immunology, Utrecht University, 3584 Utrecht, The Netherlands.
Winston ChiuLaboratory of Virology and Chemotherapy, Herestraat 49, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0001-5236-623X
Steven De JongheLaboratory of Virology and Chemotherapy, Herestraat 49, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-3872-6558
Pieter LeyssenLaboratory of Virology and Chemotherapy, Herestraat 49, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.
Denisa BojkovaInstitute for Medical Virology, University Hospital, Paul-Ehrlich-Str. 40, Frankfurt University, 60596 Frankfurt am Main, Germany.
Sandra CiesekInstitute for Medical Virology, University Hospital, Paul-Ehrlich-Str. 40, Frankfurt University, 60596 Frankfurt am Main, Germany.ORCID 0000-0002-1802-7565
Jindrich CinatlInstitute for Medical Virology, University Hospital, Paul-Ehrlich-Str. 40, Frankfurt University, 60596 Frankfurt am Main, Germany.
Lore VerschuerenJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
Christophe BuyckJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
Frank Van KuppeveldFaculty of Veterinary Medicine, Yalelaan 1, Virology Division, Department of Biomolecular Health Sciences, Infectious Diseases and Immunology, Utrecht University, 3584 Utrecht, The Netherlands.ORCID 0000-0001-5800-749X
Johan NeytsLaboratory of Virology and Chemotherapy, Herestraat 49, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-0033-7514
Marnix Van LoockJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
Ellen Van DammeJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
Janssen (Belgium) · BERega Institute for Medical Research · BEGoethe University Frankfurt · DEUtrecht University · NL

Funding

ASPR HHS HHSO100201700018C
6 · The paper itself

Abstract

The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is partly under control by vaccination. However, highly potent and safe antiviral drugs for SARS-CoV-2 are still needed to avoid development of severe COVID-19. We report the discovery of a small molecule, Z-Tyr-Ala-CHN

Indexed as

cathepsin L inhibitorcoronavirusin vitrophenotypic screeningSARS-CoV-2

Identifiers

PMID36985290
PMCPMC10055926
OpenAlexW4323844364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.